Biotron（BITR.F）株式概要バイオテクノロジー企業であるバイオトロン・リミテッドは、オーストラリアで様々なウイルス性疾患を治療するための低分子製品の開発と商業化に従事している。 詳細BITR.F ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析意味のある時価総額がありません ( $6M )過去1年間で株主の希薄化は大幅に進んだ 収益が 100 万ドル未満 ( A$-868 )株式の流動性は非常に低い すべてのリスクチェックを見るBITR.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.0011該当なし内在価値ディスカウントEst. Revenue$PastFuture-4m3m2016201920222025202620282031Revenue AU$0.9Earnings AU$0.2AdvancedSet Fair ValueView all narrativesBiotron Limited 競合他社CollPlant BiotechnologiesSymbol: NasdaqCM:CLGNMarket cap: US$6.1mAIM ImmunoTechSymbol: NYSEAM:AIMMarket cap: US$3.7mAptevo TherapeuticsSymbol: NasdaqCM:APVOMarket cap: US$5.8mFibroBiologicsSymbol: NasdaqCM:FBLGMarket cap: US$5.7m価格と性能株価の高値、安値、推移の概要Biotron過去の株価現在の株価AU$0.001152週高値AU$0.1052週安値AU$0.0011ベータ-0.551ヶ月の変化-96.56%3ヶ月変化-96.58%1年変化-88.42%3年間の変化-94.30%5年間の変化-97.38%IPOからの変化-99.21%最新ニュースお知らせ • Mar 30Biotron Limited Appoints Graeme Wald as Non-Executive Director, Effective March 30, 2026Biotron Limited announced the appointment of Graeme Wald as Non-Executive Director, effective March 30, 2026. Graeme is an Industrial Chemist and has worked as a research chemist in South Africa, Israel and the USA. He became an equities analyst and while at Merril Lynch was rated the top analyst in the Pharmaceuticals and Healthcare sector in South Africa and was a member of the top-rated Global Paper & Pulp research team. In Australia he played a leading role in growing Wilson HTM’s Life Science business to the largest in the country while Head of Lifescience research. He has extensive experience in private equity and venture capital as an Investment Director at BioScience Managers, and a Partner in Fund III at OneVentures. He has played a major role in raising more than $750M for companies in the sector and was Chairman of the Risk & Audit Committee of Nexvet Inc. while a director of the company through to its NASDAQ listing. He was also founding Chairman of Prota Therapeutics Pty Ltd. and acting CEO. He is also CEO and Director of MyrioTherapeutics Pty Ltd, a Melbourne based antibody drug company developing novel antibodies for the treatment of solid tumours and is Chairman of Psaio Therapeutics, also Melbourne based that is developing novel antibodies for the treatment of prostate cancer based on Myrio technology. He is Chairman of US based Hula Therapeutics, a private company in the clinical stage of developing a treatment for paediatric neuroblastoma, using technology partly developed by Myrio.お知らせ • Jan 30Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million.Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 215,286,751 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 292,666,664 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Rights Offeringお知らせ • Dec 02Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 199,086,664 Price\Range: AUD 0.003 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 134,246,669 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Oct 15Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 199,086,876 Price\Range: AUD 0.003 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 134,246,457 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Sep 29Biotron Limited, Annual General Meeting, Nov 17, 2025Biotron Limited, Annual General Meeting, Nov 17, 2025.お知らせ • Feb 28+ 1 more updateBiotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 652,382,667 Price\Range: AUD 0.003 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 250,000,000 Price\Range: AUD 0.003 Transaction Features: Rights Offering最新情報をもっと見るRecent updatesお知らせ • Mar 30Biotron Limited Appoints Graeme Wald as Non-Executive Director, Effective March 30, 2026Biotron Limited announced the appointment of Graeme Wald as Non-Executive Director, effective March 30, 2026. Graeme is an Industrial Chemist and has worked as a research chemist in South Africa, Israel and the USA. He became an equities analyst and while at Merril Lynch was rated the top analyst in the Pharmaceuticals and Healthcare sector in South Africa and was a member of the top-rated Global Paper & Pulp research team. In Australia he played a leading role in growing Wilson HTM’s Life Science business to the largest in the country while Head of Lifescience research. He has extensive experience in private equity and venture capital as an Investment Director at BioScience Managers, and a Partner in Fund III at OneVentures. He has played a major role in raising more than $750M for companies in the sector and was Chairman of the Risk & Audit Committee of Nexvet Inc. while a director of the company through to its NASDAQ listing. He was also founding Chairman of Prota Therapeutics Pty Ltd. and acting CEO. He is also CEO and Director of MyrioTherapeutics Pty Ltd, a Melbourne based antibody drug company developing novel antibodies for the treatment of solid tumours and is Chairman of Psaio Therapeutics, also Melbourne based that is developing novel antibodies for the treatment of prostate cancer based on Myrio technology. He is Chairman of US based Hula Therapeutics, a private company in the clinical stage of developing a treatment for paediatric neuroblastoma, using technology partly developed by Myrio.お知らせ • Jan 30Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million.Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 215,286,751 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 292,666,664 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Rights Offeringお知らせ • Dec 02Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 199,086,664 Price\Range: AUD 0.003 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 134,246,669 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Oct 15Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 199,086,876 Price\Range: AUD 0.003 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 134,246,457 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Sep 29Biotron Limited, Annual General Meeting, Nov 17, 2025Biotron Limited, Annual General Meeting, Nov 17, 2025.お知らせ • Feb 28+ 1 more updateBiotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 652,382,667 Price\Range: AUD 0.003 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 250,000,000 Price\Range: AUD 0.003 Transaction Features: Rights Offeringお知らせ • Feb 21Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 270,714,829 Price\Range: AUD 0.01お知らせ • Nov 28Biotron Limited Announces Board RetirementDr. Susan Pond and Professor Stephen Locarnini, Non-Executive Directors, have retired as Directors of Biotron Limited (Biotron) as of 28 November 2024. Dr. Pond has been a Director since 7 March 2012 and Professor Locarnini since 23 October 2018.お知らせ • Oct 22Biotron Limited, Annual General Meeting, Nov 28, 2024Biotron Limited, Annual General Meeting, Nov 28, 2024. Location: level 38 tower 3 international tower, sydney 300, barangaroo ave sydney, nsw 2000, sydney Australiaお知らせ • Oct 20Biotron Limited, Annual General Meeting, Nov 22, 2023Biotron Limited, Annual General Meeting, Nov 22, 2023, at 11:00 AUS Eastern Standard Time. Location: Level 3, 60 Carrington Street, Sydney, NSW, 2000 Sydney Australia Agenda: To receive and consider the Company's annual financial report, the directors' report and the auditors' report for the year ended 30 June 2023; to consider the That Dr. Susan M. Pond be and is hereby re-elected as a Director; to consider the That the Remuneration Report for the year ended 30 June 2023 be and is hereby adopted; to consider the Re-election of Dr. Susan M. Pond as a Director; and to consider other matters.株主還元BITR.FUS BiotechsUS 市場7D-78.0%1.2%1.1%1Y-88.4%34.6%28.7%株主還元を見る業界別リターン: BITR.F過去 1 年間で34.6 % の収益を上げたUS Biotechs業界を下回りました。リターン対市場: BITR.Fは、過去 1 年間で28.7 % のリターンを上げたUS市場を下回りました。価格変動Is BITR.F's price volatile compared to industry and market?BITR.F volatilityBITR.F Average Weekly Movementn/aBiotechs Industry Average Movement10.8%Market Average Movement7.2%10% most volatile stocks in US Market16.5%10% least volatile stocks in US Market3.1%安定した株価: BITR.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のBITR.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト1999n/aMichelle Millerwww.biotron.com.auバイオテクノロジー企業であるバイオトロン・リミテッドは、オーストラリアで様々なウイルス性疾患を治療する低分子製品の開発・商業化に従事している。同社の主力抗ウイルス薬はBIT225で、SARS-CoV-2、HIV-1、C型肝炎ウイルス感染の治療薬として第II相臨床試験中である。バイオトロン・リミテッドは1999年に設立され、オーストラリアのシドニーに本社を置いている。もっと見るBiotron Limited 基礎のまとめBiotron の収益と売上を時価総額と比較するとどうか。BITR.F 基礎統計学時価総額US$5.78m収益（TTM）-US$1.38m売上高(TTM)n/a-9,338xP/Sレシオ-4.2xPER（株価収益率BITR.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計BITR.F 損益計算書（TTM）収益-AU$868.00売上原価AU$0売上総利益-AU$868.00その他の費用AU$1.94m収益-AU$1.94m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.00072グロス・マージン100.00%純利益率223,061.06%有利子負債／自己資本比率0%BITR.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 10:05終値2026/05/22 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Biotron Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 30Biotron Limited Appoints Graeme Wald as Non-Executive Director, Effective March 30, 2026Biotron Limited announced the appointment of Graeme Wald as Non-Executive Director, effective March 30, 2026. Graeme is an Industrial Chemist and has worked as a research chemist in South Africa, Israel and the USA. He became an equities analyst and while at Merril Lynch was rated the top analyst in the Pharmaceuticals and Healthcare sector in South Africa and was a member of the top-rated Global Paper & Pulp research team. In Australia he played a leading role in growing Wilson HTM’s Life Science business to the largest in the country while Head of Lifescience research. He has extensive experience in private equity and venture capital as an Investment Director at BioScience Managers, and a Partner in Fund III at OneVentures. He has played a major role in raising more than $750M for companies in the sector and was Chairman of the Risk & Audit Committee of Nexvet Inc. while a director of the company through to its NASDAQ listing. He was also founding Chairman of Prota Therapeutics Pty Ltd. and acting CEO. He is also CEO and Director of MyrioTherapeutics Pty Ltd, a Melbourne based antibody drug company developing novel antibodies for the treatment of solid tumours and is Chairman of Psaio Therapeutics, also Melbourne based that is developing novel antibodies for the treatment of prostate cancer based on Myrio technology. He is Chairman of US based Hula Therapeutics, a private company in the clinical stage of developing a treatment for paediatric neuroblastoma, using technology partly developed by Myrio.
お知らせ • Jan 30Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million.Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 215,286,751 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 292,666,664 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Rights Offering
お知らせ • Dec 02Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 199,086,664 Price\Range: AUD 0.003 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 134,246,669 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Oct 15Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 199,086,876 Price\Range: AUD 0.003 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 134,246,457 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Sep 29Biotron Limited, Annual General Meeting, Nov 17, 2025Biotron Limited, Annual General Meeting, Nov 17, 2025.
お知らせ • Feb 28+ 1 more updateBiotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 652,382,667 Price\Range: AUD 0.003 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 250,000,000 Price\Range: AUD 0.003 Transaction Features: Rights Offering
お知らせ • Mar 30Biotron Limited Appoints Graeme Wald as Non-Executive Director, Effective March 30, 2026Biotron Limited announced the appointment of Graeme Wald as Non-Executive Director, effective March 30, 2026. Graeme is an Industrial Chemist and has worked as a research chemist in South Africa, Israel and the USA. He became an equities analyst and while at Merril Lynch was rated the top analyst in the Pharmaceuticals and Healthcare sector in South Africa and was a member of the top-rated Global Paper & Pulp research team. In Australia he played a leading role in growing Wilson HTM’s Life Science business to the largest in the country while Head of Lifescience research. He has extensive experience in private equity and venture capital as an Investment Director at BioScience Managers, and a Partner in Fund III at OneVentures. He has played a major role in raising more than $750M for companies in the sector and was Chairman of the Risk & Audit Committee of Nexvet Inc. while a director of the company through to its NASDAQ listing. He was also founding Chairman of Prota Therapeutics Pty Ltd. and acting CEO. He is also CEO and Director of MyrioTherapeutics Pty Ltd, a Melbourne based antibody drug company developing novel antibodies for the treatment of solid tumours and is Chairman of Psaio Therapeutics, also Melbourne based that is developing novel antibodies for the treatment of prostate cancer based on Myrio technology. He is Chairman of US based Hula Therapeutics, a private company in the clinical stage of developing a treatment for paediatric neuroblastoma, using technology partly developed by Myrio.
お知らせ • Jan 30Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million.Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 215,286,751 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 292,666,664 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Rights Offering
お知らせ • Dec 02Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 199,086,664 Price\Range: AUD 0.003 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 134,246,669 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Oct 15Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 199,086,876 Price\Range: AUD 0.003 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 134,246,457 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Sep 29Biotron Limited, Annual General Meeting, Nov 17, 2025Biotron Limited, Annual General Meeting, Nov 17, 2025.
お知らせ • Feb 28+ 1 more updateBiotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 652,382,667 Price\Range: AUD 0.003 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 250,000,000 Price\Range: AUD 0.003 Transaction Features: Rights Offering
お知らせ • Feb 21Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 270,714,829 Price\Range: AUD 0.01
お知らせ • Nov 28Biotron Limited Announces Board RetirementDr. Susan Pond and Professor Stephen Locarnini, Non-Executive Directors, have retired as Directors of Biotron Limited (Biotron) as of 28 November 2024. Dr. Pond has been a Director since 7 March 2012 and Professor Locarnini since 23 October 2018.
お知らせ • Oct 22Biotron Limited, Annual General Meeting, Nov 28, 2024Biotron Limited, Annual General Meeting, Nov 28, 2024. Location: level 38 tower 3 international tower, sydney 300, barangaroo ave sydney, nsw 2000, sydney Australia
お知らせ • Oct 20Biotron Limited, Annual General Meeting, Nov 22, 2023Biotron Limited, Annual General Meeting, Nov 22, 2023, at 11:00 AUS Eastern Standard Time. Location: Level 3, 60 Carrington Street, Sydney, NSW, 2000 Sydney Australia Agenda: To receive and consider the Company's annual financial report, the directors' report and the auditors' report for the year ended 30 June 2023; to consider the That Dr. Susan M. Pond be and is hereby re-elected as a Director; to consider the That the Remuneration Report for the year ended 30 June 2023 be and is hereby adopted; to consider the Re-election of Dr. Susan M. Pond as a Director; and to consider other matters.
